Melanoma & Skin Cancer

The combination of atezolizumab and cobimetinib may lead to a higher overall response and a longer progression-free survival than either agent alone in patients with metastatic melanoma.

Christian Blank, MD, PhD, Netherlands Cancer Institute, discusses some of the early findings from the OpACIN trial testing a combination of ipilimumab and nivolumab in the neoadjuvant and adjuvant setting for patients with stage III melanoma.

Neoadjuvant therapy with the combination of nivolumab and ipilimumab is plausible and effective but can induce a high level of adverse events calling for further research into better tolerated dosing schemes.

Ryan Sullivan, MD, Massachusetts General Hospital, discusses how best to treat patients with melanoma who have the BRAF mutation.

The addition of the PD-L1 inhibitor atezolizumab to the MEK inhibitor cobimetinib and the BRAF inhibitor vemurafenib induced a high response rate for patients with BRAF-mutant unresectable melanoma.

Jason Luke, MD, an assistant professor of Medicine at the University of Chicago Medicine, discusses the role for immunotherapy and targeted agents in patients with BRAF-positive melanoma.

The European Medicines Agency has accepted and validated a marketing authorization application for avelumab as a treatment for patients with metastatic Merkel cell carcinoma.

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses some of the exciting advancements seen with immunotherapy in the treatment of patients with melanoma.

Yvonne Saenger, MD, director of Melanoma Immunotherapy at Columbia University Medical Center, discusses the importance of developing accurate biomarkers when it comes to administering immunotherapy.